---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-027337"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:51:33.981172+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics reports 2024 net loss $152.1M; atacicept Phase 3 primary endpoint due Q2 2025

## Summary
- Net loss of $152.1M ($2.75 diluted EPS) vs $96.0M ($2.25) in 2023; cash burn $134.7M operating.
- Cash and equivalents $640.9M as of Dec 31, 2024; sufficient through potential 2026 commercial launch.
- Phase 3 ORIGIN trial primary endpoint expected Q2 2025; BLA submission for atacicept planned H2 2025.
- Expanded pipeline: atacicept in PMN, FSGS, MCD; acquired next-gen fusion protein VT-109 in 2024.
- FDA Breakthrough Therapy Designation granted for atacicept in IgAN during 2024.

## SEC filing metadata
- accession: 0000950170-25-027337
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000095017025027337/0000950170-25-027337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000095017025027337/vera-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-027337
- JSON: https://secwatch.observer/filing/0000950170-25-027337.json
- Plain text: https://secwatch.observer/filing/0000950170-25-027337.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.